Over a week ago
Hot Stocks
Integer Holdings…
Integer Holdings announced the opening of The Galway Research and Development, R&D, Innovation Centre in Ireland. The new facility will further enhance Integer's capability to provide high-quality medical devices and technologies that help sustain and save the lives of patients worldwide. The Galway R&D Innovation Centre will enable Integer to provide a collaborative environment where both Integer and our customers' teams can work together to ideate and develop new and innovative devices. "Integer continues to make key investments to help support our customers' innovation and growth," said Payman Khales, president of Integer's cardio and vascular business. "The Galway R&D Innovation Centre will allow us to enhance our current capabilities, while accelerating the development of a broad range of cardio and vascular products." Located in Claregalway, six kilometers from Integer's main Galway, Ireland, facility, the new, fully dedicated 8,500 square foot facility will support Integer's customers across the globe, including the significant medical device cluster in Ireland. The facility features a versatile workspace for the R&D team to collaborate with customers on innovative technical solutions that meet their evolving needs. There is also a significant increase in development lab space, providing the team room to grow and add capabilities, including space for a cleanroom pilot line. In addition, the opening of this new dedicated facility, frees up space allowing the Galway manufacturing site to expand, increase capacity and add new equipment as required to meet customers' needs.
Show Hide Related Items >> <<
02/19/20 Integer acquires Inomec, terms undisclosed 01/24/20 Integer announces expanded active implantable medical device capabilities 05/14/20 Benchmark Benchmark starts Integer at Buy after 'strong' Q1 report 05/14/20 Benchmark Integer initiated with a Buy at Benchmark 02/20/20 Integer sees FY20 adj. EPS $5.10-$5.30, consensus $5.00 02/20/20 Integer reports Q4 adj. EPS $1.25, consensus $1.17
Conference/Events
Virtual Meeting to be…
Virtual Meeting to be held on June 24 hosted by KeyBanc.
Show Hide Related Items >> <<
02/19/20 Integer acquires Inomec, terms undisclosed 01/24/20 Integer announces expanded active implantable medical device capabilities 05/14/20 Benchmark Benchmark starts Integer at Buy after 'strong' Q1 report 05/14/20 Benchmark Integer initiated with a Buy at Benchmark 02/20/20 Integer sees FY20 adj. EPS $5.10-$5.30, consensus $5.00 02/20/20 Integer reports Q4 adj. EPS $1.25, consensus $1.17
Conference/Events
Virtual Meeting to be…
Virtual Meeting to be held on June 24 hosted by KeyBanc.
Show Hide Related Items >> <<
02/19/20 Integer acquires Inomec, terms undisclosed 01/24/20 Integer announces expanded active implantable medical device capabilities 05/14/20 Benchmark Benchmark starts Integer at Buy after 'strong' Q1 report 05/14/20 Benchmark Integer initiated with a Buy at Benchmark 02/20/20 Integer sees FY20 adj. EPS $5.10-$5.30, consensus $5.00 02/20/20 Integer reports Q4 adj. EPS $1.25, consensus $1.17
Over a quarter ago
Conference/Events
Global Healthcare…
Global Healthcare Conference 2020 will be held in Miami on March 10-12.
Show Hide Related Items >> <<
02/07/20 Baird AmerisourceBergen upgraded to Outperform at Baird 02/07/20 Baird AmerisourceBergen upgraded to Outperform from Neutral at Baird 01/28/20 Cleveland Research AmerisourceBergen appears to be gaining share, says Cleveland Research 10/16/19 Jefferies Drug distributor settlement would make stocks 'ownable again,' says Jefferies AMAG Amag Pharmaceuticals 03/04/20 Piper Sandler Amag Pharmaceuticals price target lowered to $7 from $9 at Piper Sandler 03/03/20 H.C. Wainwright Amag Pharmaceuticals price target lowered to $12 from $16 at H.C. Wainwright 01/09/20 Piper Sandler Amag business still facing 'significant challenges,' says Piper Sandler 11/04/19 Barclays Amag Pharmaceuticals price target lowered to $14 from $16 at Barclays 02/28/20 Cowen AstaZeneca pipeline leads to best European idea, says Cowen 01/27/20 William Blair PhaseBio could see increase to PB2452 addressable market, says William Blair 01/22/20 Liberum Sanofi downgraded to Hold from Buy at Liberum (earlier) 01/22/20 Oppenheimer Amarin price target raised to $13 from $8 at Oppenheimer 12/30/19 Stifel Avanos makes 'welcome addition' with 'highly experienced' CFO, says Stifel 11/06/19 Stifel Avanos downgraded to Hold from Buy at Stifel 11/06/19 Stifel Avanos downgraded to Hold from Buy at Stifel 11/06/19 Raymond James Avanos shares could be range-bound over next six months, says Raymond James 03/04/20 Citi Becton Dickinson initiated with a Neutral at Citi 03/02/20 Wells Fargo Baxter, J&J best positioned to weather coronavirus spread, says Wells Fargo 02/07/20 Fly Intel: Top five analyst downgrades 02/07/20 Raymond James Becton Dickinson downgraded at Raymond James given pump overhang $345.64 / -21.41 (-5.83%)
03/03/20 Citi Bio-Rad margin expansion story in early innings, says Citi 01/07/20 Wells Fargo Wells Fargo initiates Life Science Tools, Services, Diagnostics Sector 01/07/20 Wells Fargo Bio-Rad initiated with an Overweight at Wells Fargo 01/06/20 Citi Citi calls Bio-Rad, Thermo Fisher top picks in Tools industry 02/12/20 Morgan Stanley Cardinal Health upgraded to Equal Weight from Underweight at Morgan Stanley 02/07/20 Baird Cardinal Health upgraded to Outperform at Baird 02/07/20 Mizuho Cardinal Health price target raised to $58 from $52 at Mizuho 02/07/20 Baird Cardinal Health upgraded to Outperform from Neutral at Baird 02/25/20 Fly Intel: Top five analyst initiations 02/25/20 RBC Capital Clovis initiated with an Outperform at RBC Capital 01/08/20 H.C. Wainwright Clovis price target lowered to $27 from $36 at H.C. Wainwright 01/07/20 Piper Sandler Clovis modestly extends cash runway with debt deal, says Piper Sandler $323.96 / -10.03 (-3.00%)
03/06/20 Baird Cooper Companies price target raised to $357 from $345 at Baird 03/06/20 Piper Sandler Cooper Companies price target raised to $351 from $344 at Piper Sandler 03/04/20 Citi Cooper Companies initiated with a Neutral at Citi 02/20/20 Stephens Stephens watching near-term MCO stock reactions after Bloomberg's 'rough' debate 02/18/20 Deutsche Bank Deutsche raises price targets in Managed Care on fading political risks 02/10/20 Cowen CVS upside to guidance seen, says Cowen 01/21/20 Cantor Fitzgerald CVS, Cigna and Centene a buy on any block grant selloff, says Cantor 03/06/20 Jefferies COVID-19 tests unlikely to move needle for Quest or LabCorp, says Jefferies 03/05/20 JPMorgan Quest Diagnostics' COVID-19 testing to be small benefit for 2020, says JPMorgan 02/10/20 Mizuho Quest Diagnostics price target raised to $122 from $116 at Mizuho 01/30/20 Piper Sandler Quest Diagnostics price target raised to $107 from $102 at Piper Sandler 02/24/20 Credit Suisse eHealth price target raised to $179 from $145 at Credit Suisse 02/21/20 SunTrust eHealth price target raised to $250 from $200 at SunTrust 02/21/20 Craig-Hallum eHealth price target raised to $200 from $150 at Craig-Hallum 02/21/20 RBC Capital eHealth price target raised to $166 from $132 at RBC Capital 03/04/20 Barclays Barclays starts small, mid cap Biotechnology sector with Positive view 03/04/20 Barclays Exelixis initiated with an Overweight at Barclays 02/27/20 Piper Sandler Exelixis price target lowered to $23 from $35 at Piper Sandler 02/11/20 Piper Sandler Exelixis data 'impressive,' support accelerated approval, says Piper Sandler 03/04/20 Citi Fate Therapeutics price target raised to $41 from $26 at Citi 03/04/20 Barclays Fate Therapeutics initiated with an Overweight at Barclays 03/03/20 BMO Capital Fate Therapeutics price target raised to $28 from $22 at BMO Capital 02/11/20 Piper Sandler Fluidigm price target lowered to $9 from $14 at Piper Sandler 01/14/20 Piper Sandler Piper Sandler reiterates Overweight on Fluidigm after Q4 results, guidance 11/06/19 Janney Montgomery Scott Fluidigm downgraded to Neutral after Q3 miss at Janney Montgomery Scott 11/06/19 Janney Montgomery Scott Fluidigm downgraded to Neutral from Buy at Janney Montgomery Scott 03/05/20 Berenberg Fresenius Medical price target lowered to EUR 89.70 from EUR 89.95 at Berenberg 01/21/20 Jefferies Fresenius Medical upgraded to Buy from Hold at Jefferies 12/06/19 Morgan Stanley Fresenius Medical downgraded to Underweight from Equal Weight at Morgan Stanley 10/23/19 Redburn Redburn downgrades Fresenius Medical to Neutral on growth concerns 07/26/19 Fly Intel: Top five analyst initiations 07/25/19 Baird Gritstone Oncology initiated with an Outperform at Baird 03/27/19 Berenberg Gritstone Oncology initiated with a Buy at Berenberg 03/14/19 Raymond James Gritstone Oncology initiated with an Outperform at Raymond James 12/17/19 Morgan Stanley Hill-Rom upgraded to Overweight on accelerating momentum at Morgan Stanley 12/17/19 Morgan Stanley Hill-Rom upgraded to Overweight from Equal Weight at Morgan Stanley 06/27/19 Raymond James Hill-Rom's DoD contract win a 'nice development,' says Raymond James $328.50 / -20.52 (-5.88%)
01/23/20 UBS Humana price target raised to $406 from $321 at UBS 01/08/20 Credit Suisse Humana price target raised to $400 from $378 at Credit Suisse 02/24/20 Jefferies Epizyme, Blueprint among cancer companies that fit M&A criteria, says Jefferies 01/02/20 Guggenheim Incyte downgraded to Neutral after strong 2019 at Guggenheim 12/27/19 H.C. Wainwright Immunomedics price target raised to $31 from $26 at H.C. Wainwright 12/20/19 BofA Immunomedics initiated with a Buy at BofA/Merrill 08/05/19 Credit Suisse Ironwood assumed with a Neutral at Credit Suisse 07/10/19 Credit Suisse Ironwood assumed with a Neutral at Credit Suisse 03/27/19 Morgan Stanley Morgan Stanley upgrades Ironwood to Equal Weight on more stable Linzess growth 03/27/19 Morgan Stanley Ironwood upgraded to Equal Weight from Underweight at Morgan Stanley 06/05/19 Argus Integer price target lowered to $90 from $103 at Argus JAZZ Jazz Pharmaceuticals 02/26/20 RBC Capital Jazz Pharmaceuticals price target lowered to $164 from $184 at RBC Capital 02/26/20 Oppenheimer Jazz Pharmaceuticals price target lowered to $154 from $183 at Oppenheimer 02/26/20 Cowen Jazz Pharmaceuticals lowered his price target to $165 from $200 at Cowen 02/26/20 Piper Sandler Jazz Pharmaceuticals price target lowered to $129 from $142 at Piper Sandler $131.65 / -10.05 (-7.09%)
03/11/20 H.C. Wainwright H.C. Wainwright reiterates Buy on Genmab following J&J drug announcement 03/06/20 Credit Suisse Johnson & Johnson price target lowered to $159 from $170 at Credit Suisse 03/04/20 Citi Johnson & Johnson initiated with a Buy at Citi 03/04/20 Fly Intel: Top five analyst initiations 03/04/20 Cantor Fitzgerald Ziopharm initiated with Overweight, $6 price target at Cantor Fitzgerald 03/03/20 Cantor Fitzgerald Ziopharm initiated with an Overweight at Cantor Fitzgerald 08/23/19 Fly Intel: Top five analyst initiations VNDA Vanda Pharmaceuticals 03/12/20 Citi Vanda Pharmaceuticals upgraded to Buy from Neutral at Citi 02/27/20 Oppenheimer Vanda Pharmaceuticals price target lowered to $12 from $18 at Oppenheimer 02/26/20 JMP Securities Vanda Pharmaceuticals price target lowered to $25 from $52 at JMP Securities 11/07/19 Citi Citi downgrades Vanda to Neutral after 'excessive' post-earnings rally 03/04/20 Stifel Qiagen deal a positive for Thermo Fisher, says Stifel 03/04/20 Berenberg Qiagen downgraded to Hold from Buy at Berenberg 03/03/20 Piper Sandler Danaher unlikely to make competing bid for Qiagen, says Piper Sandler 02/05/20 Piper Sandler Qiagen price target raised to $36 from $29 at Piper Sandler 03/05/20 Fly Intel: Top five analyst downgrades 03/05/20 BofA Moderna downgraded to Neutral from Buy at BofA 03/05/20 BofA Moderna downgraded to Neutral from Buy at BofA 03/04/20 Piper Sandler Moderna's Manufacturing & Digital Day showcases its mRNA advantages, says Piper 02/07/20 UBS Mettler-Toledo upgraded to Neutral from Sell at UBS 01/07/20 Wells Fargo Mettler-Toledo initiated with an Equal Weight at Wells Fargo 01/06/20 Citi Mettler-Toledo initiated with a Neutral at Citi 01/02/20 Evercore ISI Mettler-Toledo upgraded to In Line from Underperform at Evercore ISI 02/27/20 Barclays Molecular Templates initiated with an Overweight at Barclays 02/27/20 Barclays Molecular Templates initiated with an Overweight at Barclays 04/29/19 UBS Molecular Templates initiated with a Buy at UBS 02/27/20 Piper Sandler Natera price target raised to $49 from $45 at Piper Sandler 12/19/19 Craig-Hallum Natera kidney test to be covered under Medicare in February, says Craig-Hallum 12/19/19 Piper Sandler CareDx should be bought on weakness from Natera coverage, says Piper 11/11/19 Canaccord Natera results solid, remains a top pick at Canaccord 03/04/20 Citi Insulet initiated with a Buy at Citi 03/02/20 Piper Sandler Insulet should be bought on selloff from trial delay, says Piper Sandler 02/26/20 Cowen Insulet weakness a buying opportunity, says Cowen 02/26/20 Raymond James Insulet price target lowered to $205 from $213 at Raymond James 03/03/20 Cantor Fitzgerald PTC Therapeutics price target raised to $86 from $81 at Cantor Fitzgerald 02/20/20 RBC Capital PTC Therapeutics downgraded to Sector Perform from Outperform at RBC Capital 02/20/20 Citi PTC Therapeutics downgraded to Neutral from Buy at Citi 02/20/20 RBC Capital PTC Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
Conference/Events
Global Healthcare…
Global Healthcare Conference 2020 will be held in Miami on March 10-12.
Show Hide Related Items >> <<
02/07/20 Baird AmerisourceBergen upgraded to Outperform at Baird 02/07/20 Baird AmerisourceBergen upgraded to Outperform from Neutral at Baird 01/28/20 Cleveland Research AmerisourceBergen appears to be gaining share, says Cleveland Research 10/16/19 Jefferies Drug distributor settlement would make stocks 'ownable again,' says Jefferies AMAG Amag Pharmaceuticals 03/04/20 Piper Sandler Amag Pharmaceuticals price target lowered to $7 from $9 at Piper Sandler 03/03/20 H.C. Wainwright Amag Pharmaceuticals price target lowered to $12 from $16 at H.C. Wainwright 01/09/20 Piper Sandler Amag business still facing 'significant challenges,' says Piper Sandler 11/04/19 Barclays Amag Pharmaceuticals price target lowered to $14 from $16 at Barclays 02/28/20 Cowen AstaZeneca pipeline leads to best European idea, says Cowen 01/27/20 William Blair PhaseBio could see increase to PB2452 addressable market, says William Blair 01/22/20 Liberum Sanofi downgraded to Hold from Buy at Liberum (earlier) 01/22/20 Oppenheimer Amarin price target raised to $13 from $8 at Oppenheimer 12/30/19 Stifel Avanos makes 'welcome addition' with 'highly experienced' CFO, says Stifel 11/06/19 Stifel Avanos downgraded to Hold from Buy at Stifel 11/06/19 Stifel Avanos downgraded to Hold from Buy at Stifel 11/06/19 Raymond James Avanos shares could be range-bound over next six months, says Raymond James 03/04/20 Citi Becton Dickinson initiated with a Neutral at Citi 03/02/20 Wells Fargo Baxter, J&J best positioned to weather coronavirus spread, says Wells Fargo 02/07/20 Fly Intel: Top five analyst downgrades 02/07/20 Raymond James Becton Dickinson downgraded at Raymond James given pump overhang 03/03/20 Citi Bio-Rad margin expansion story in early innings, says Citi 01/07/20 Wells Fargo Wells Fargo initiates Life Science Tools, Services, Diagnostics Sector 01/07/20 Wells Fargo Bio-Rad initiated with an Overweight at Wells Fargo 01/06/20 Citi Citi calls Bio-Rad, Thermo Fisher top picks in Tools industry 02/12/20 Morgan Stanley Cardinal Health upgraded to Equal Weight from Underweight at Morgan Stanley 02/07/20 Baird Cardinal Health upgraded to Outperform at Baird 02/07/20 Mizuho Cardinal Health price target raised to $58 from $52 at Mizuho 02/07/20 Baird Cardinal Health upgraded to Outperform from Neutral at Baird 02/25/20 Fly Intel: Top five analyst initiations 02/25/20 RBC Capital Clovis initiated with an Outperform at RBC Capital 01/08/20 H.C. Wainwright Clovis price target lowered to $27 from $36 at H.C. Wainwright 01/07/20 Piper Sandler Clovis modestly extends cash runway with debt deal, says Piper Sandler $333.99 / +16.38 (+5.16%)
03/06/20 Baird Cooper Companies price target raised to $357 from $345 at Baird 03/06/20 Piper Sandler Cooper Companies price target raised to $351 from $344 at Piper Sandler 03/04/20 Citi Cooper Companies initiated with a Neutral at Citi 02/20/20 Stephens Stephens watching near-term MCO stock reactions after Bloomberg's 'rough' debate 02/18/20 Deutsche Bank Deutsche raises price targets in Managed Care on fading political risks 02/10/20 Cowen CVS upside to guidance seen, says Cowen 01/21/20 Cantor Fitzgerald CVS, Cigna and Centene a buy on any block grant selloff, says Cantor 03/06/20 Jefferies COVID-19 tests unlikely to move needle for Quest or LabCorp, says Jefferies 03/05/20 JPMorgan Quest Diagnostics' COVID-19 testing to be small benefit for 2020, says JPMorgan 02/10/20 Mizuho Quest Diagnostics price target raised to $122 from $116 at Mizuho 01/30/20 Piper Sandler Quest Diagnostics price target raised to $107 from $102 at Piper Sandler 02/24/20 Credit Suisse eHealth price target raised to $179 from $145 at Credit Suisse 02/21/20 SunTrust eHealth price target raised to $250 from $200 at SunTrust 02/21/20 Craig-Hallum eHealth price target raised to $200 from $150 at Craig-Hallum 02/21/20 RBC Capital eHealth price target raised to $166 from $132 at RBC Capital 03/04/20 Barclays Barclays starts small, mid cap Biotechnology sector with Positive view 03/04/20 Barclays Exelixis initiated with an Overweight at Barclays 02/27/20 Piper Sandler Exelixis price target lowered to $23 from $35 at Piper Sandler 02/11/20 Piper Sandler Exelixis data 'impressive,' support accelerated approval, says Piper Sandler 03/04/20 Citi Fate Therapeutics price target raised to $41 from $26 at Citi 03/04/20 Barclays Fate Therapeutics initiated with an Overweight at Barclays 03/03/20 BMO Capital Fate Therapeutics price target raised to $28 from $22 at BMO Capital 02/11/20 Piper Sandler Fluidigm price target lowered to $9 from $14 at Piper Sandler 01/14/20 Piper Sandler Piper Sandler reiterates Overweight on Fluidigm after Q4 results, guidance 11/06/19 Janney Montgomery Scott Fluidigm downgraded to Neutral after Q3 miss at Janney Montgomery Scott 11/06/19 Janney Montgomery Scott Fluidigm downgraded to Neutral from Buy at Janney Montgomery Scott 03/05/20 Berenberg Fresenius Medical price target lowered to EUR 89.70 from EUR 89.95 at Berenberg 01/21/20 Jefferies Fresenius Medical upgraded to Buy from Hold at Jefferies 12/06/19 Morgan Stanley Fresenius Medical downgraded to Underweight from Equal Weight at Morgan Stanley 10/23/19 Redburn Redburn downgrades Fresenius Medical to Neutral on growth concerns 07/26/19 Fly Intel: Top five analyst initiations 07/25/19 Baird Gritstone Oncology initiated with an Outperform at Baird 03/27/19 Berenberg Gritstone Oncology initiated with a Buy at Berenberg 03/14/19 Raymond James Gritstone Oncology initiated with an Outperform at Raymond James 12/17/19 Morgan Stanley Hill-Rom upgraded to Overweight on accelerating momentum at Morgan Stanley 12/17/19 Morgan Stanley Hill-Rom upgraded to Overweight from Equal Weight at Morgan Stanley 06/27/19 Raymond James Hill-Rom's DoD contract win a 'nice development,' says Raymond James $349.02 / +11.84 (+3.51%)
01/23/20 UBS Humana price target raised to $406 from $321 at UBS 01/08/20 Credit Suisse Humana price target raised to $400 from $378 at Credit Suisse 02/24/20 Jefferies Epizyme, Blueprint among cancer companies that fit M&A criteria, says Jefferies 01/02/20 Guggenheim Incyte downgraded to Neutral after strong 2019 at Guggenheim 12/27/19 H.C. Wainwright Immunomedics price target raised to $31 from $26 at H.C. Wainwright 12/20/19 BofA Immunomedics initiated with a Buy at BofA/Merrill 08/05/19 Credit Suisse Ironwood assumed with a Neutral at Credit Suisse 07/10/19 Credit Suisse Ironwood assumed with a Neutral at Credit Suisse 03/27/19 Morgan Stanley Morgan Stanley upgrades Ironwood to Equal Weight on more stable Linzess growth 03/27/19 Morgan Stanley Ironwood upgraded to Equal Weight from Underweight at Morgan Stanley 06/05/19 Argus Integer price target lowered to $90 from $103 at Argus JAZZ Jazz Pharmaceuticals 02/26/20 RBC Capital Jazz Pharmaceuticals price target lowered to $164 from $184 at RBC Capital 02/26/20 Oppenheimer Jazz Pharmaceuticals price target lowered to $154 from $183 at Oppenheimer 02/26/20 Cowen Jazz Pharmaceuticals lowered his price target to $165 from $200 at Cowen 02/26/20 Piper Sandler Jazz Pharmaceuticals price target lowered to $129 from $142 at Piper Sandler 03/06/20 Credit Suisse Johnson & Johnson price target lowered to $159 from $170 at Credit Suisse 03/04/20 Citi Johnson & Johnson initiated with a Buy at Citi 01/27/20 Credit Suisse Johnson & Johnson price target raised to $170 from $163 at Credit Suisse 03/04/20 Fly Intel: Top five analyst initiations 03/04/20 Cantor Fitzgerald Ziopharm initiated with Overweight, $6 price target at Cantor Fitzgerald 03/03/20 Cantor Fitzgerald Ziopharm initiated with an Overweight at Cantor Fitzgerald 08/23/19 Fly Intel: Top five analyst initiations VNDA Vanda Pharmaceuticals 02/27/20 Oppenheimer Vanda Pharmaceuticals price target lowered to $12 from $18 at Oppenheimer 02/26/20 JMP Securities Vanda Pharmaceuticals price target lowered to $25 from $52 at JMP Securities 11/07/19 Citi Citi downgrades Vanda to Neutral after 'excessive' post-earnings rally 11/07/19 Citi Vanda Pharmaceuticals downgraded to Neutral from Buy at Citi 03/04/20 Stifel Qiagen deal a positive for Thermo Fisher, says Stifel 03/04/20 Berenberg Qiagen downgraded to Hold from Buy at Berenberg 03/03/20 Piper Sandler Danaher unlikely to make competing bid for Qiagen, says Piper Sandler 02/05/20 Piper Sandler Qiagen price target raised to $36 from $29 at Piper Sandler 03/05/20 Fly Intel: Top five analyst downgrades 03/05/20 BofA Moderna downgraded to Neutral from Buy at BofA 03/05/20 BofA Moderna downgraded to Neutral from Buy at BofA 03/04/20 Piper Sandler Moderna's Manufacturing & Digital Day showcases its mRNA advantages, says Piper $696.68 / +25.36 (+3.78%)
02/07/20 UBS Mettler-Toledo upgraded to Neutral from Sell at UBS 01/07/20 Wells Fargo Mettler-Toledo initiated with an Equal Weight at Wells Fargo 01/06/20 Citi Mettler-Toledo initiated with a Neutral at Citi 01/02/20 Evercore ISI Mettler-Toledo upgraded to In Line from Underperform at Evercore ISI 02/27/20 Barclays Molecular Templates initiated with an Overweight at Barclays 02/27/20 Barclays Molecular Templates initiated with an Overweight at Barclays 04/29/19 UBS Molecular Templates initiated with a Buy at UBS 02/27/20 Piper Sandler Natera price target raised to $49 from $45 at Piper Sandler 12/19/19 Craig-Hallum Natera kidney test to be covered under Medicare in February, says Craig-Hallum 12/19/19 Piper Sandler CareDx should be bought on weakness from Natera coverage, says Piper 11/11/19 Canaccord Natera results solid, remains a top pick at Canaccord 03/04/20 Citi Insulet initiated with a Buy at Citi 03/02/20 Piper Sandler Insulet should be bought on selloff from trial delay, says Piper Sandler 02/26/20 Cowen Insulet weakness a buying opportunity, says Cowen 02/26/20 Raymond James Insulet price target lowered to $205 from $213 at Raymond James 03/03/20 Cantor Fitzgerald PTC Therapeutics price target raised to $86 from $81 at Cantor Fitzgerald 02/20/20 RBC Capital PTC Therapeutics downgraded to Sector Perform from Outperform at RBC Capital 02/20/20 Citi PTC Therapeutics downgraded to Neutral from Buy at Citi 02/20/20 RBC Capital PTC Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
Conference/Events
Global Healthcare…
Global Healthcare Conference 2020 will be held in Miami on March 10-12.
Show Hide Related Items >> <<
02/07/20 Baird AmerisourceBergen upgraded to Outperform at Baird 02/07/20 Baird AmerisourceBergen upgraded to Outperform from Neutral at Baird 01/28/20 Cleveland Research AmerisourceBergen appears to be gaining share, says Cleveland Research 10/16/19 Jefferies Drug distributor settlement would make stocks 'ownable again,' says Jefferies AMAG Amag Pharmaceuticals 03/04/20 Piper Sandler Amag Pharmaceuticals price target lowered to $7 from $9 at Piper Sandler 03/03/20 H.C. Wainwright Amag Pharmaceuticals price target lowered to $12 from $16 at H.C. Wainwright 01/09/20 Piper Sandler Amag business still facing 'significant challenges,' says Piper Sandler 11/04/19 Barclays Amag Pharmaceuticals price target lowered to $14 from $16 at Barclays 02/28/20 Cowen AstaZeneca pipeline leads to best European idea, says Cowen 01/27/20 William Blair PhaseBio could see increase to PB2452 addressable market, says William Blair 01/22/20 Liberum Sanofi downgraded to Hold from Buy at Liberum (earlier) 01/22/20 Oppenheimer Amarin price target raised to $13 from $8 at Oppenheimer 12/30/19 Stifel Avanos makes 'welcome addition' with 'highly experienced' CFO, says Stifel 11/06/19 Stifel Avanos downgraded to Hold from Buy at Stifel 11/06/19 Stifel Avanos downgraded to Hold from Buy at Stifel 11/06/19 Raymond James Avanos shares could be range-bound over next six months, says Raymond James 03/04/20 Citi Becton Dickinson initiated with a Neutral at Citi 03/02/20 Wells Fargo Baxter, J&J best positioned to weather coronavirus spread, says Wells Fargo 02/07/20 Fly Intel: Top five analyst downgrades 02/07/20 Raymond James Becton Dickinson downgraded at Raymond James given pump overhang $352.05 / -23.16 (-6.17%)
03/03/20 Citi Bio-Rad margin expansion story in early innings, says Citi 01/07/20 Wells Fargo Wells Fargo initiates Life Science Tools, Services, Diagnostics Sector 01/07/20 Wells Fargo Bio-Rad initiated with an Overweight at Wells Fargo 01/06/20 Citi Citi calls Bio-Rad, Thermo Fisher top picks in Tools industry 02/12/20 Morgan Stanley Cardinal Health upgraded to Equal Weight from Underweight at Morgan Stanley 02/07/20 Baird Cardinal Health upgraded to Outperform at Baird 02/07/20 Mizuho Cardinal Health price target raised to $58 from $52 at Mizuho 02/07/20 Baird Cardinal Health upgraded to Outperform from Neutral at Baird 02/25/20 Fly Intel: Top five analyst initiations 02/25/20 RBC Capital Clovis initiated with an Outperform at RBC Capital 01/08/20 H.C. Wainwright Clovis price target lowered to $27 from $36 at H.C. Wainwright 01/07/20 Piper Sandler Clovis modestly extends cash runway with debt deal, says Piper Sandler $317.61 / -15.52 (-4.66%)
03/06/20 Baird Cooper Companies price target raised to $357 from $345 at Baird 03/06/20 Piper Sandler Cooper Companies price target raised to $351 from $344 at Piper Sandler 03/04/20 Citi Cooper Companies initiated with a Neutral at Citi 02/20/20 Stephens Stephens watching near-term MCO stock reactions after Bloomberg's 'rough' debate 02/18/20 Deutsche Bank Deutsche raises price targets in Managed Care on fading political risks 02/10/20 Cowen CVS upside to guidance seen, says Cowen 01/21/20 Cantor Fitzgerald CVS, Cigna and Centene a buy on any block grant selloff, says Cantor 03/06/20 Jefferies COVID-19 tests unlikely to move needle for Quest or LabCorp, says Jefferies 03/05/20 JPMorgan Quest Diagnostics' COVID-19 testing to be small benefit for 2020, says JPMorgan 02/10/20 Mizuho Quest Diagnostics price target raised to $122 from $116 at Mizuho 01/30/20 Piper Sandler Quest Diagnostics price target raised to $107 from $102 at Piper Sandler 02/24/20 Credit Suisse eHealth price target raised to $179 from $145 at Credit Suisse 02/21/20 SunTrust eHealth price target raised to $250 from $200 at SunTrust 02/21/20 Craig-Hallum eHealth price target raised to $200 from $150 at Craig-Hallum 02/21/20 RBC Capital eHealth price target raised to $166 from $132 at RBC Capital 03/04/20 Barclays Barclays starts small, mid cap Biotechnology sector with Positive view 03/04/20 Barclays Exelixis initiated with an Overweight at Barclays 02/27/20 Piper Sandler Exelixis price target lowered to $23 from $35 at Piper Sandler 02/11/20 Piper Sandler Exelixis data 'impressive,' support accelerated approval, says Piper Sandler 03/04/20 Citi Fate Therapeutics price target raised to $41 from $26 at Citi 03/04/20 Barclays Fate Therapeutics initiated with an Overweight at Barclays 03/03/20 BMO Capital Fate Therapeutics price target raised to $28 from $22 at BMO Capital 02/11/20 Piper Sandler Fluidigm price target lowered to $9 from $14 at Piper Sandler 01/14/20 Piper Sandler Piper Sandler reiterates Overweight on Fluidigm after Q4 results, guidance 11/06/19 Janney Montgomery Scott Fluidigm downgraded to Neutral after Q3 miss at Janney Montgomery Scott 11/06/19 Janney Montgomery Scott Fluidigm downgraded to Neutral from Buy at Janney Montgomery Scott 03/05/20 Berenberg Fresenius Medical price target lowered to EUR 89.70 from EUR 89.95 at Berenberg 01/21/20 Jefferies Fresenius Medical upgraded to Buy from Hold at Jefferies 12/06/19 Morgan Stanley Fresenius Medical downgraded to Underweight from Equal Weight at Morgan Stanley 10/23/19 Redburn Redburn downgrades Fresenius Medical to Neutral on growth concerns 07/26/19 Fly Intel: Top five analyst initiations 07/25/19 Baird Gritstone Oncology initiated with an Outperform at Baird 03/27/19 Berenberg Gritstone Oncology initiated with a Buy at Berenberg 03/14/19 Raymond James Gritstone Oncology initiated with an Outperform at Raymond James 12/17/19 Morgan Stanley Hill-Rom upgraded to Overweight on accelerating momentum at Morgan Stanley 12/17/19 Morgan Stanley Hill-Rom upgraded to Overweight from Equal Weight at Morgan Stanley 06/27/19 Raymond James Hill-Rom's DoD contract win a 'nice development,' says Raymond James $337.18 / -29.73 (-8.10%)
01/23/20 UBS Humana price target raised to $406 from $321 at UBS 01/08/20 Credit Suisse Humana price target raised to $400 from $378 at Credit Suisse 02/24/20 Jefferies Epizyme, Blueprint among cancer companies that fit M&A criteria, says Jefferies 01/02/20 Guggenheim Incyte downgraded to Neutral after strong 2019 at Guggenheim 12/27/19 H.C. Wainwright Immunomedics price target raised to $31 from $26 at H.C. Wainwright 12/20/19 BofA Immunomedics initiated with a Buy at BofA/Merrill 08/05/19 Credit Suisse Ironwood assumed with a Neutral at Credit Suisse 07/10/19 Credit Suisse Ironwood assumed with a Neutral at Credit Suisse 03/27/19 Morgan Stanley Morgan Stanley upgrades Ironwood to Equal Weight on more stable Linzess growth 03/27/19 Morgan Stanley Ironwood upgraded to Equal Weight from Underweight at Morgan Stanley 06/05/19 Argus Integer price target lowered to $90 from $103 at Argus JAZZ Jazz Pharmaceuticals 02/26/20 RBC Capital Jazz Pharmaceuticals price target lowered to $164 from $184 at RBC Capital 02/26/20 Oppenheimer Jazz Pharmaceuticals price target lowered to $154 from $183 at Oppenheimer 02/26/20 Cowen Jazz Pharmaceuticals lowered his price target to $165 from $200 at Cowen 02/26/20 Piper Sandler Jazz Pharmaceuticals price target lowered to $129 from $142 at Piper Sandler 03/06/20 Credit Suisse Johnson & Johnson price target lowered to $159 from $170 at Credit Suisse 03/04/20 Citi Johnson & Johnson initiated with a Buy at Citi 01/27/20 Credit Suisse Johnson & Johnson price target raised to $170 from $163 at Credit Suisse 03/04/20 Fly Intel: Top five analyst initiations 03/04/20 Cantor Fitzgerald Ziopharm initiated with Overweight, $6 price target at Cantor Fitzgerald 03/03/20 Cantor Fitzgerald Ziopharm initiated with an Overweight at Cantor Fitzgerald 08/23/19 Fly Intel: Top five analyst initiations VNDA Vanda Pharmaceuticals 02/27/20 Oppenheimer Vanda Pharmaceuticals price target lowered to $12 from $18 at Oppenheimer 02/26/20 JMP Securities Vanda Pharmaceuticals price target lowered to $25 from $52 at JMP Securities 11/07/19 Citi Citi downgrades Vanda to Neutral after 'excessive' post-earnings rally 11/07/19 Citi Vanda Pharmaceuticals downgraded to Neutral from Buy at Citi 03/04/20 Stifel Qiagen deal a positive for Thermo Fisher, says Stifel 03/04/20 Berenberg Qiagen downgraded to Hold from Buy at Berenberg 03/03/20 Piper Sandler Danaher unlikely to make competing bid for Qiagen, says Piper Sandler 02/05/20 Piper Sandler Qiagen price target raised to $36 from $29 at Piper Sandler 03/05/20 Fly Intel: Top five analyst downgrades 03/05/20 BofA Moderna downgraded to Neutral from Buy at BofA 03/05/20 BofA Moderna downgraded to Neutral from Buy at BofA 03/04/20 Piper Sandler Moderna's Manufacturing & Digital Day showcases its mRNA advantages, says Piper $671.32 / -43.68 (-6.11%)
02/07/20 UBS Mettler-Toledo upgraded to Neutral from Sell at UBS 01/07/20 Wells Fargo Mettler-Toledo initiated with an Equal Weight at Wells Fargo 01/06/20 Citi Mettler-Toledo initiated with a Neutral at Citi 01/02/20 Evercore ISI Mettler-Toledo upgraded to In Line from Underperform at Evercore ISI 02/27/20 Barclays Molecular Templates initiated with an Overweight at Barclays 02/27/20 Barclays Molecular Templates initiated with an Overweight at Barclays 04/29/19 UBS Molecular Templates initiated with a Buy at UBS 02/27/20 Piper Sandler Natera price target raised to $49 from $45 at Piper Sandler 12/19/19 Craig-Hallum Natera kidney test to be covered under Medicare in February, says Craig-Hallum 12/19/19 Piper Sandler CareDx should be bought on weakness from Natera coverage, says Piper 11/11/19 Canaccord Natera results solid, remains a top pick at Canaccord 03/04/20 Citi Insulet initiated with a Buy at Citi 03/02/20 Piper Sandler Insulet should be bought on selloff from trial delay, says Piper Sandler 02/26/20 Cowen Insulet weakness a buying opportunity, says Cowen 02/26/20 Raymond James Insulet price target lowered to $205 from $213 at Raymond James 03/03/20 Cantor Fitzgerald PTC Therapeutics price target raised to $86 from $81 at Cantor Fitzgerald 02/20/20 RBC Capital PTC Therapeutics downgraded to Sector Perform from Outperform at RBC Capital 02/20/20 Citi PTC Therapeutics downgraded to Neutral from Buy at Citi 02/20/20 RBC Capital PTC Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
Earnings
Sees revenue…
Sees revenue $1.29B-$1.31B, consensus $1.29B.
Show Hide Related Items >> <<
06/05/19 Argus Integer price target lowered to $90 from $103 at Argus
Earnings
Reports Q4 revenue $326M,…
Reports Q4 revenue $326M, consensus $321.33M. "Integer delivered strong earnings growth in 2019 as our Manufacturing Excellence strategic imperative is delivering operational and financial improvements. We exceeded our original 2019 adjusted profit guidance as we continue to deliver on our commitments to investors. We further strengthened our leadership team to enable us to accelerate the execution of our strategy and deliver for our customers," said Joseph Dziedzic, Integer's president and chief executive officer. "Yesterday we completed a bolt-on acquisition, which further strengthens our R&D capabilities and expands our global footprint into Israel, which is widely recognized as a leading innovation center. Our 2020 financial guidance delivers on our commitment to grow profit at least twice as fast as our sales growth rate, while making investments to execute our remaining strategic financial objective to deliver above market revenue growth."
Show Hide Related Items >> <<
06/05/19 Argus Integer price target lowered to $90 from $103 at Argus